Journal of Arak University of Medical Sciences

Search published articles

Showing 4 results for Atorvastatin

Association Between Atorvastatin Therapy and Reduction in Pacemaker Peak Threshold in Patient with Permanent Pacemaker

Valiollah Khadir Srabiany,
Volume 17, Issue 10 (1-2015)

Abstract

Background: Statins are the most effective drugs for treatment of elevated level of cholesterol. In addition, they exhibit other effects unrelated to their lipid lowering effects (pleiotropic actions). In recent years, experimental and clinical evidences demonstrate that statins exert anti-inflammatory properties. The aim of this study is evaluation of association Atorvastatin in reduction of peak threshold in patients with permanent pacemaker.

Materials and Methods: In these clinical trial 64 eligible patients that candidate for permanent pacemaker enrolled. After in formed consent patients randomly divided to two equal groups. In first group atorvastatin 20 mg/daily administered orally for six weeks and second group considered as control. Peak atrial and ventricular threshold were measured in beginning of study and in sixth week. The data collected and analyzed and p<0.05 considered statistically meaning full.

Results: from 32 subjects in Atorvastatin group 17 (53.12%) were male and 15(46.87%) were female. Average mean age in Atorvastatin and control group was 72.43±17.27 and 68.59 ±10.98 years, respectively. No difference showed in atrial and ventricular threshold in two groups at beginning of study. At end of study atrial threshold in atorvastatin and control group were 0.55±0.23 and 0.45±0.19 respectively (p=0.4) and ventricular threshold in atorvastatin and and control group were 0.73±0.23 (p=0.4).

Conclusion: There is no association between atorvastatin therapy and reduction in pacemaker peak arterial and ventricular threshold.

The Effect of Atorvastatin on Inflammatory Markers in Patients with Type Two Diabetes

Afsaneh Talaei, Mehdi Mahmoudpoor, Maryam Shahdost,
Volume 21, Issue 4 (8-2018)

Abstract

Background and Aim: Regarding to paradoxical results of the studies about the effects of atorvastatin on inflammatory markers and metabolism, we aimed to evaluate the effects of atorvastatin on inflammatory markers in diabetic patients.
Materials and Methods: Through a double blind randomized clinical trial, placebo control, 88 type two diabetic patients (T2DP), were treated with anti-diabetes oral agents, were randomly classified into two 44 cases groups. The intervention group took atorvastatin 40 mg daily and control group took placebo for three months and adiponectin, hsCRP, leptin, TNF-α, lipid profile and fasting blood glucose (FBS) were measured and compared at the beginning and the end of the study. The data were analyzed using student t test and paired t test.
Findings: After three months, adiponectin was significantly increased in intervention group in comparison to control group, but leptin had not a significant change in two groups. Total cholesterol, hsCRP and LDL cholesterol (Low density Lipoprotein) were decreased significantly in the intervention group than control group, while FBS was
non-significantly decreased.
Conclusion: It seems atorvastatin is effective to decrease inflammatopry markers in diabetic patients.

Comparative Investigation of the Effect of Quercetin and Hydroalcoholic Extract of Otostegia Persica Boiss with Atorvastatin on ABC A1 Gene Expression in Hypercholesterolemic Male Wistar Rats

Ali Parvin, Parichehreh Yaghmaei, Mahdi Noureddini, Sayyed Ali Haeri Roohani, Saeed Aminzadeh,
Volume 22, Issue 1 (4-2019)

Abstract

Background and Aim: Hypercholesterolemia is an independent risk factor for atherosclerosis that the use of medicinal plants with minimal side effects is very important in the treatment of it. In this study, comparative evaluation of the effect of hydroalcoholic extract and quercetin of Otostegia persica Boiss with atorvastatin on ABC A1 gene expression in hypercholesterolemic male Wistar rats was carried out.
Materials and Methods: Forty male wistar rats with about 180gr weight randomly individed into five groups of eight: 3 experimental groups, 1 sham group and 1 control group. The experimental and sham groups received a high-fat diet with 2% cholesterol (through gavage) for 40 days. The experimental groups were treated (were fed) separately with 40 mg/kg/day atorvastatin, 25 mg/kg/day quercetin and 25 mg/kg/day hydroalcoholic extract of Otostegia persica Boiss for 28 days. Sham group received daily 1 mg/kg saline water during this period. In the end, the expression of ABC A1 gene was determined by Real-Time PCR in leukocytes and serum lipids were measured by photometric method.
Ethical Considerations: This study with research ethics code B/29/5/1/1799 has been approved by committee for ethics in biomedical research at Kashan university of medical sciensec on July 31, 2016.
Findings: The hydroalcoholic extract and quercetin of Otostegia persica Boiss and atorvastatin significantly increased ABC A1 gene expression in three experimental groups {(1.14 ± 0.09) ,(1.18 ± 0.03),(1.11 ± 0.03) respectively} realated to control group(1.00 ± 0.011) (p<0.05) and sham group(0.89 ± 0.03) (p<0.05). Quercetin also was more effective than atorvastatin in increasing of ABC A1 gene expression (p<0.05).
Conclusion: Quercetin and hydroalcoholic extract of Otostegia persica Boiss have increased effect on ABC A1 gene expression in hypercholesterolemic male Wistar rats.

The Effect of Atorvastatin on Inslin Resistance in Patients with Type Two Diabetes

Afsaneh Talaei, Mehdi Mahmudpour, Maryam Shahdost,
Volume 22, Issue 2 (6-2019)

Abstract

Background and Aim: Regarding the controversy about the effects of atorvastatin on blood glucose control and diabetes, we evaluated the effects of atorvastatin on blood glucose and insulin resistance in the present study.
Materials and Methods: 88 type two diabetic patients (T2DP), were treated with anti-diabetes oral agents were enrolled in a double blind randomized clinical trial, placebo control. Then they were randomly classified into two 44 cases groups. The intervention group took atorvastatin 40 mg daily and control group took placebo for three months and fasting blood glucose (FBS), insulin resistance, HbA1c and lipid profile were measured and compared at the beginning and the end of the study. Data were analyzed using student t-test and paired t-test.
Ethical Considerations: This study with research ethics code IR.ARAKMU.REC.90.108.10 has been approved by research ethics committee at Arak University of Medical Sciences.
Findings: After three months, insulin, insulin resistance and HbA1c decreased significantly in the intervention group than control group, while FBS non-significantly decreased. Total cholesterol and LDL cholesterol (Low density Lipoprotein) were also decreased.
Conclusion: It seems atorvastatin is effective to decrease FBS and insulin resistance in diabetic patients.

Page 1 from 1

Designed & Developed by : Yektaweb